Pfizer’s Biosimilars Grow By A Tenth
As First-Half Sales Of Sterile Injectables Slip By A Similar Proportion
Pfizer has reported healthy growth of a tenth for its biosimilars portfolio in the first half of 2022, at the same time as its sterile injectables sales slipped by a similar degree.
